MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$50,067K
Net cash provided by
financing activities
$1,445K
Canceled cashflow
$48,622K
Net decrease in cash
and cash...
-$16,182K
Canceled cashflow
$1,445K
Stock-based compensation
$3,318K
Non-cash interest
expense
$2,475K
Loss on
extinguishment of debt
-$1,533K
Deferred revenue
$782K
Change in obligation
for r&d funding...
$754K
Amortization of finance lease
right-of-use asset
$352K
Amortization of operating
lease right-of-use...
$296K
Loss on disposal of
fixed assets
-$246K
Accounts payable
$176K
Depreciation expense
$133K
Non-cash r&d expense
related to warrant...
$51K
Loss on termination
of financing lease
-$1K
Cash paid to settle
debt
$35,030K
Repayment of debt
$12,789K
Repayment of finance lease
$383K
Issuance costs for common
stock, pre-funded...
$310K
Debt amendment costs
$110K
Net cash used in
operating activities
-$17,627K
Canceled cashflow
$10,117K
Total revenue
$35,577K
Net loss
-$17,886K
Canceled cashflow
$35,577K
Accounts receivable
$5,212K
Change in fair value of
derivative liability
$2,648K
Accrued expenses and
other current...
-$1,311K
Operating lease liability
-$315K
Prepaid expenses and
other assets
$264K
Collaboration receivable,
billed and unbilled
$108K
Total selling,
general and...
$35,220K
Total research and
development
$8,855K
Other segment items
$5,701K
Cost of product
revenue
$2,192K
Cost of license and
collaboration revenue
$1,249K
Loss on disposal of
assets
-$246K
Back
Back
Cash Flow
source: myfinsight.com
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)